Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...

Late on Thursday night and into the early hours of Friday, the full moon turned a beautiful reddish color as it drifted ...

An automated 3D vision-guided robotic system has been developed by Goldfuß Engineering and SIMON IBV to accelerate the ...

Early crew members of the voyaging canoe Hokulea have gathered in Hawaii to celebrate the vessel's 50th birthday. The Hokulea ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the ...

Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $30 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...